Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

21.47
+0.74003.57%
Post-market: 21.770.3000+1.40%19:57 EDT
Volume:6.49M
Turnover:133.98M
Market Cap:2.72B
PE:-11.77
High:21.80
Open:21.00
Low:19.25
Close:20.73
52wk High:35.72
52wk Low:16.10
Shares:126.53M
Float Shares:78.12M
Volume Ratio:1.67
T/O Rate:8.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8245
EPS(LYR):-1.5970
ROE:14.10%
ROA:5.13%
PB:6.77
PE(LYR):-13.44

Loading ...

Aug 30, 2021

Major Issues Report

8-K - Current report
Aug 19, 2021

Major Issues Report

8-K - Current report
Aug 09, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 26, 2021

Major Issues Report

8-K - Current report
Jul 08, 2021

Major Issues Report

8-K - Current report
Jun 30, 2021

Major Issues Report

8-K - Current report
Jun 01, 2021

Major Issues Report

8-K - Current report
Apr 28, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 11, 2021

Major Issues Report

8-K - Current report
Feb 25, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 25, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 05, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 03, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 26, 2021

Major Issues Report

8-K - Current report
Jan 07, 2021

Major Issues Report

8-K - Current report
Jan 04, 2021

Major Issues Report

8-K - Current report
Nov 02, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]